Virus News and Research

Latest Virus News and Research

AlphaRx, Venturepharm sign supply agreement for ARX1088's API

AlphaRx Inc. announced today that it has signed an agreement that provides long-term supply of the active pharmaceutical ingredient (API) for ARX1088, an orally active interferon inducer intended for the adjunctive treatment of Hepatitis in China and other emerging markets. Under the agreement, Venturepharm will be the primary supplier of AlphaRx's worldwide requirements for the compound.

17 Dec 2009

Anadys Pharmaceuticals reports positive 4-week results from its ANA598 Phase II study for HCV

Anadys Pharmaceuticals, Inc. today announced preliminary results from a planned interim analysis of data at four weeks for the first dose cohort, 200 mg bid, in an ongoing Phase II study of ANA598 in combination with pegylated interferon and ribavirin (SOC) in HCV patients.

17 Dec 2009

Tips for healthy living for the year ahead

Whether you are a vegetarian, vegan, carnivore or pescetarian, vegetables should be a central part of your diet. Often referred to as a "protective food," dark green foods provide essential vitamins and nutrients to your body that protect you from many of life's worst diseases.

17 Dec 2009

Risk of H1N1 exposure alters U.S. holiday plans

Forty percent of U.S. adults intend to change their holiday plans due to the risk of being exposed to the H1N1 flu virus, according to a nationwide survey commissioned by JohnsonDiversey, a global leader in the commercial cleaning and sanitizing industry.

17 Dec 2009

Cubist Pharmaceuticals acquires Calixa Therapeutics

Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company has completed its previously announced acquisition of Calixa Therapeutics Inc.,

17 Dec 2009

Diagnostic Nano Technology to use Instant Detect Technology to detect H1N1 virus

Diagnostic Nano Technology Corporation (DNA), a subsidiary of Avisio, Inc., announced today that with the early laboratory success of its Instant Detect Technology in the detection of certain viruses that cause Dengue Fever, it plans to begin testing the technology on the detection of the H1N1 virus.

17 Dec 2009

Infection control program protects immunocompromised cancer patients from H1N1 infection

Despite a 100-fold increase in H1N1 influenza cases in the Seattle area during spring 2009, an aggressive infection control program to protect immunocompromised cancer patients and thorough screening measures resulted in no corresponding increase in H1N1 cases among the total patient population at the Seattle Cancer Care Alliance, according to a new study by researchers and physicians at Fred Hutchinson Cancer Research Center and the SCCA.

17 Dec 2009

GSK and NanoBio sign license agreement for nanoemulsion technology

GlaxoSmithKline and Ann Arbor-based NanoBio Corporation announced today that they have signed an exclusive over-the-counter licensing agreement for NanoBio's unique nanoemulsion treatment for cold sores in the United States and Canada.

17 Dec 2009

Scientists draw on bacterial decision-making success to guide human choices on H1N1 vaccine

Bacteria inhabited our planet for more than 4 billion years before humans showed up, and they'll probably outlive us by as many eons more. That suggests they may have something to teach us.

17 Dec 2009

WHO using new bivalent oral polio vaccine in Afghanistan

The WHO on Tuesday launched a vaccination campaign in Afghanistan that will use "a new and more effective polio vaccine" for the first time, Reuters reports (Nebehay, 12/15).

16 Dec 2009

NanoBio, GSK partner to develop and commercialize novel cold sore treatment compound

GlaxoSmithKline plc and NanoBio Corporation today announced an exclusive licensing agreement in the United States and Canada for the over-the-counter (OTC) use of NB-001, a novel, patented compound representing the next advance in the treatment of cold sores. Developed by NanoBio, NB-001 provides significant antimicrobial activity against the virus that causes cold sores, herpes labialis.

16 Dec 2009

Walgreens offers H1N1 vaccine in 27 states

Walgreens, the nation’s largest drugstore chain and an industry leader with more than 17,000 certified or licensed immunizers, today announced it is offering H1N1 vaccine at more than 1,500 Walgreens pharmacies and select Take Care Clinics in 27 states, as well as the District of Columbia.

16 Dec 2009

Pennsylvania expands H1N1 vaccination program to everyone

Certified healthcare providers who have already immunized patients most at risk of complications from the H1N1 flu virus may now offer the vaccine to anyone who wants it, the Department of Health announced today.

16 Dec 2009

Immune system produces neutralizing antibodies capable of blocking HIV, says study

Scientists seeking to understand how to make an AIDS vaccine have found the cause of a major roadblock. It turns out that the immune system can indeed produce cells with the potential to manufacture powerful HIV-blocking antibodies - but at the same time, the immune system works equally hard to make sure these cells are eliminated before they have a chance to mature.

16 Dec 2009

Infectious virus particles can bind to the surface of red blood cells: MHRP researchers

Free infectious HIV-1 is widely thought to be the major form of the virus in the blood of infected persons. U.S. Military HIV Research Program (MHRP) researchers, however, have demonstrated that essentially all of the infectious virus particles can bind to the surface of red blood cells isolated from each of 30 normal (non-infected) human donors.

16 Dec 2009

Drug monitoring may provide alternative treatments for patients with severe H1N1

An international team of Canadian and Spanish scientists have found the first potential immunological clue of why some people develop severe pneumonia when infected by the pandemic H1N1 virus.

16 Dec 2009

USPTO issues Notice of Allowance for U.S. patent application in the 'Crooke' patent family

Isis Pharmaceuticals, Inc. and Alnylam Pharmaceuticals, Inc. announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. patent application (No. 10/078,949) in the “Crooke” patent family, which broadly covers chemically modified RNA-containing therapeutics.

16 Dec 2009

Advaxis to collaborate with GOG in Phase II clinical trial of ADXS11-001

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) vaccine company, will collaborate with the Gynecologic Oncology Group (GOG), a collaborative research group of the National Cancer Institute (NCI), in a multicenter, Phase II clinical trial of the Company’s lead drug candidate, ADXS11-001 in the treatment of advanced cervix cancer in women who have failed prior cytotoxic therapy.

15 Dec 2009

Also in Global Health news: Drug trafficking in Kenya; violence in S. Sudan; Uganda bill; sleeping sickness

Drug trafficking and use are fueling the spread of HIV/AIDS in Kenya, according to a recent report by the U.N. Security Council, the Nation reports. "A statement from the council's Presidency currently … states that Afghan heroin was being imported, causing a dramatic increase in heroin addiction and spreading HIV/AIDS in the slums of Nairobi and Mombasa, Kenya's two main cities," the newspaper writes.

15 Dec 2009

Novartis submits JOULFERON MAA to the EMEA

Human Genome Sciences, Inc. today announced that Novartis has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMEA) for approval to market JOULFERON® (albinterferon alfa-2b, known in the United States as ZALBIN™) for the treatment of chronic hepatitis C. In November 2009, HGS submitted a Biologics License Application (BLA) for ZALBIN to the FDA in the United States.

15 Dec 2009

Virus News and Research

Latest Virus News and Research

AlphaRx, Venturepharm sign supply agreement for ARX1088's API

Anadys Pharmaceuticals reports positive 4-week results from its ANA598 Phase II study for HCV

Tips for healthy living for the year ahead

Risk of H1N1 exposure alters U.S. holiday plans

Cubist Pharmaceuticals acquires Calixa Therapeutics

Diagnostic Nano Technology to use Instant Detect Technology to detect H1N1 virus

Infection control program protects immunocompromised cancer patients from H1N1 infection

GSK and NanoBio sign license agreement for nanoemulsion technology

Scientists draw on bacterial decision-making success to guide human choices on H1N1 vaccine

WHO using new bivalent oral polio vaccine in Afghanistan

NanoBio, GSK partner to develop and commercialize novel cold sore treatment compound

Walgreens offers H1N1 vaccine in 27 states

Pennsylvania expands H1N1 vaccination program to everyone

Immune system produces neutralizing antibodies capable of blocking HIV, says study

Infectious virus particles can bind to the surface of red blood cells: MHRP researchers

Drug monitoring may provide alternative treatments for patients with severe H1N1

USPTO issues Notice of Allowance for U.S. patent application in the 'Crooke' patent family

Advaxis to collaborate with GOG in Phase II clinical trial of ADXS11-001

Also in Global Health news: Drug trafficking in Kenya; violence in S. Sudan; Uganda bill; sleeping sickness

Novartis submits JOULFERON MAA to the EMEA

A new way of characterising biomolecules eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Virus News and Research

Latest Virus News and Research

A new way of characterising biomolecules eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in